BC-3781 Passes Phase 2 with Flying Colors, Readies for Phase 3

The pleuromutilins are a relatively ‘old’ class of antibiotics that have seen much use in veterinary but not in human medicine.  According to EMA, Tiamulin is an “essential antibiotic” for the control of dysentery in pigs which is caused by Brachyspira hyodysenteriae, a macrolide-resistant pathogen.[1]  Retapamulin / Altabax® was introduced Continue reading BC-3781 Passes Phase 2 with Flying Colors, Readies for Phase 3

Why The Next Novel Antibiotic Will Be A Blockbuster And Cost $40k

Looking at all antibiotics in the pipeline, I can’t help but think that – by 2018 – there will be some blockbuster anti-infectives coming to the market. Why do I say this?  What is going to generate this revenue stream for companies when the new crop of drugs will be restricted by Continue reading Why The Next Novel Antibiotic Will Be A Blockbuster And Cost $40k

The Antibiotic Pipeline: How “New” is New

In a recent ‘Viewpoint’ article, Dr. Fauci, Director of NIAID, mentioned that “industry has expanded the pipeline of new antibacterial drugs…with 14-agents currently in phase 3 clinical trials”.[1] Regarding the number of drugs in late development, his statement may be correct but many of these drugs are anything but new.  Reviewing Continue reading The Antibiotic Pipeline: How “New” is New